StageZero Life Sciences Ltd. (SZLSF)
USD 0.02
(533.33%)
USD 0.02
(533.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 7.34 Million USD | -20.17% |
| 2021 | 9.3 Million USD | 129.79% |
| 2020 | 4.05 Million USD | -3.08% |
| 2019 | 4.17 Million USD | 27.1% |
| 2018 | 3.28 Million USD | -21.06% |
| 2017 | 4.16 Million USD | 8.19% |
| 2016 | 3.84 Million USD | 21.2% |
| 2015 | 3.17 Million USD | -24.47% |
| 2014 | 4.2 Million USD | -19.92% |
| 2013 | 5.25 Million USD | 12.7% |
| 2012 | 4.65 Million USD | 21.37% |
| 2011 | 3.83 Million USD | -13.6% |
| 2010 | 4.44 Million USD | -25.89% |
| 2009 | 5.99 Million USD | -51.18% |
| 2008 | 12.28 Million USD | -2.53% |
| 2007 | 12.6 Million USD | 16.76% |
| 2006 | 10.79 Million USD | 46.5% |
| 2005 | 7.36 Million USD | 12.02% |
| 2004 | 6.57 Million USD | 102.89% |
| 2003 | 3.24 Million USD | 213.67% |
| 2002 | 1.03 Million USD | -26.3% |
| 2001 | 1.4 Million USD | 468.19% |
| 2000 | 246.73 Thousand USD | 782.44% |
| 1999 | 27.96 Thousand USD | 311.01% |
| 1998 | 6802.73 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 595.77 Thousand USD | 0.0% |
| 2024 Q2 | 703.1 Thousand USD | 18.01% |
| 2023 Q3 | 929.14 Thousand USD | -1.4% |
| 2023 Q1 | 1.42 Million USD | 8.42% |
| 2023 Q2 | 942.3 Thousand USD | -33.81% |
| 2022 Q1 | 2.59 Million USD | -14.5% |
| 2022 Q3 | 1.58 Million USD | -19.38% |
| 2022 Q2 | 1.97 Million USD | -24.04% |
| 2022 FY | 7.43 Million USD | -20.17% |
| 2022 Q4 | 1.31 Million USD | -17.37% |
| 2021 Q1 | 1.75 Million USD | 24.33% |
| 2021 Q3 | 2.37 Million USD | 11.49% |
| 2021 Q4 | 3.03 Million USD | 27.55% |
| 2021 Q2 | 2.13 Million USD | 21.3% |
| 2021 FY | 9.3 Million USD | 129.79% |
| 2020 Q3 | 1.04 Million USD | 53.76% |
| 2020 Q4 | 1.41 Million USD | 35.98% |
| 2020 FY | 4.05 Million USD | -3.08% |
| 2020 Q1 | 663.56 Thousand USD | -40.89% |
| 2020 Q2 | 676.8 Thousand USD | 2.0% |
| 2019 FY | 4.17 Million USD | 27.1% |
| 2019 Q1 | 1 Million USD | 36.03% |
| 2019 Q4 | 1.12 Million USD | -5.89% |
| 2019 Q3 | 1.19 Million USD | 7.28% |
| 2019 Q2 | 1.11 Million USD | 11.19% |
| 2018 Q4 | 735.14 Thousand USD | -20.71% |
| 2018 FY | 3.28 Million USD | -21.06% |
| 2018 Q1 | 829.74 Thousand USD | -14.57% |
| 2018 Q2 | 837.14 Thousand USD | 0.89% |
| 2018 Q3 | 927.18 Thousand USD | 10.76% |
| 2017 Q1 | 1.03 Million USD | 88.87% |
| 2017 FY | 4.16 Million USD | 8.19% |
| 2017 Q3 | 1.06 Million USD | -2.66% |
| 2017 Q4 | 971.3 Thousand USD | -8.9% |
| 2017 Q2 | 1.09 Million USD | 6.1% |
| 2016 FY | 3.84 Million USD | 21.2% |
| 2016 Q1 | 675.13 Thousand USD | -7.47% |
| 2016 Q4 | 546.55 Thousand USD | -60.68% |
| 2016 Q3 | 1.39 Million USD | 12.29% |
| 2016 Q2 | 1.23 Million USD | 83.37% |
| 2015 Q1 | 753.24 Thousand USD | -40.37% |
| 2015 Q2 | 980.96 Thousand USD | 30.23% |
| 2015 Q3 | 688.61 Thousand USD | -29.8% |
| 2015 FY | 3.17 Million USD | -24.47% |
| 2015 Q4 | 729.65 Thousand USD | 5.96% |
| 2014 FY | 4.2 Million USD | -19.92% |
| 2014 Q4 | 1.26 Million USD | 50.99% |
| 2014 Q3 | 836.55 Thousand USD | -32.14% |
| 2014 Q2 | 1.23 Million USD | 31.62% |
| 2014 Q1 | 936.61 Thousand USD | 26.09% |
| 2013 FY | 5.25 Million USD | 12.7% |
| 2013 Q4 | 742.8 Thousand USD | -50.04% |
| 2013 Q3 | 1.48 Million USD | -9.53% |
| 2013 Q2 | 1.64 Million USD | 20.48% |
| 2013 Q1 | 1.36 Million USD | 47.17% |
| 2012 Q2 | 1.14 Million USD | 3.87% |
| 2012 Q4 | 926.91 Thousand USD | -35.09% |
| 2012 Q1 | 1.1 Million USD | -2.46% |
| 2012 Q3 | 1.42 Million USD | 24.47% |
| 2012 FY | 4.65 Million USD | 21.37% |
| 2011 FY | 3.83 Million USD | -13.6% |
| 2011 Q1 | 1.02 Million USD | 5.41% |
| 2011 Q2 | 948.35 Thousand USD | -7.64% |
| 2011 Q3 | 3.24 Million USD | 242.18% |
| 2011 Q4 | 1.13 Million USD | -65.11% |
| 2010 Q3 | 1.06 Million USD | -4.38% |
| 2010 Q4 | 974.16 Thousand USD | -8.66% |
| 2010 Q2 | 1.11 Million USD | -12.8% |
| 2010 Q1 | 1.27 Million USD | 50.75% |
| 2010 FY | 4.44 Million USD | -25.89% |
| 2009 Q4 | 848.47 Thousand USD | -44.77% |
| 2009 Q2 | 1.49 Million USD | -10.87% |
| 2009 Q1 | 1.68 Million USD | 17.57% |
| 2009 Q3 | 1.53 Million USD | 2.57% |
| 2009 FY | 5.99 Million USD | -51.18% |
| 2008 Q4 | 1.42 Million USD | -64.18% |
| 2008 Q1 | 2.86 Million USD | -55.06% |
| 2008 Q2 | 4.23 Million USD | 47.82% |
| 2008 Q3 | 3.99 Million USD | -5.86% |
| 2008 FY | 12.28 Million USD | -2.53% |
| 2007 FY | 12.6 Million USD | 16.76% |
| 2007 Q1 | 3.04 Million USD | 20.31% |
| 2007 Q2 | 2.5 Million USD | -17.88% |
| 2007 Q3 | 2.67 Million USD | 6.89% |
| 2007 Q4 | 6.37 Million USD | 138.31% |
| 2006 Q4 | 2.53 Million USD | -12.4% |
| 2006 Q3 | 2.89 Million USD | 11.73% |
| 2006 Q2 | 2.58 Million USD | -2.7% |
| 2006 Q1 | 2.66 Million USD | 66.06% |
| 2006 FY | 10.79 Million USD | 46.5% |
| 2005 Q2 | 1.85 Million USD | 9.8% |
| 2005 Q3 | 2.05 Million USD | 10.95% |
| 2005 FY | 7.36 Million USD | 12.02% |
| 2005 Q4 | 1.6 Million USD | -22.03% |
| 2005 Q1 | 1.68 Million USD | -11.11% |
| 2004 FY | 6.57 Million USD | 102.89% |
| 2004 Q2 | 1.63 Million USD | 29.28% |
| 2004 Q4 | 1.89 Million USD | 16.11% |
| 2004 Q1 | 1.26 Million USD | -6.9% |
| 2004 Q3 | 1.63 Million USD | 0.03% |
| 2003 Q2 | 636.23 Thousand USD | 26.51% |
| 2003 Q3 | 703.26 Thousand USD | 10.53% |
| 2003 Q4 | 1.35 Million USD | 93.09% |
| 2003 Q1 | 502.91 Thousand USD | 22.48% |
| 2003 FY | 3.24 Million USD | 213.67% |
| 2002 FY | 1.03 Million USD | -26.3% |
| 2002 Q4 | 410.6 Thousand USD | -18.32% |
| 2002 Q1 | 488.88 Thousand USD | 50.61% |
| 2002 Q2 | 853.23 Thousand USD | 74.53% |
| 2002 Q3 | 502.67 Thousand USD | -41.09% |
| 2001 Q1 | 482.62 Thousand USD | 57.66% |
| 2001 FY | 1.4 Million USD | 468.19% |
| 2001 Q4 | 324.59 Thousand USD | 52.61% |
| 2001 Q3 | 212.69 Thousand USD | -38.28% |
| 2001 Q2 | 344.61 Thousand USD | -28.6% |
| 2000 Q4 | 306.12 Thousand USD | 9.16% |
| 2000 Q3 | 280.42 Thousand USD | 0.0% |
| 2000 Q1 | 8107.18 USD | 31.04% |
| 2000 FY | 246.73 Thousand USD | 782.44% |
| 1999 FY | 27.96 Thousand USD | 311.01% |
| 1999 Q4 | 6186.75 USD | 32.57% |
| 1999 Q1 | 7333.11 USD | 0.0% |
| 1999 Q3 | 4666.96 USD | -52.56% |
| 1999 Q2 | 9837.30 USD | 34.15% |
| 1998 FY | 6802.73 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -600.002% |
| Arrayit Corporation | 6.19 Million USD | -18.482% |
| Atlantic International Corp. | 5.57 Million USD | -31.636% |
| Biocept, Inc. | 29.4 Million USD | 75.025% |
| Bioqual, Inc. | 7.44 Million USD | 1.42% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -850.993% |
| DermTech, Inc. | 104.01 Million USD | 92.94% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 95.59% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 67.543% |
| iMD Companies, Inc. | 151.8 Thousand USD | -4737.01% |
| IDenta Corp. | 662.97 Thousand USD | -1007.586% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 63.706% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -18785.872% |
| InVitro International | 661.32 Thousand USD | -1010.351% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -3.452% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -12535.972% |
| Medical Imaging Corp. | 1.91 Million USD | -284.016% |
| NovelStem International Corp. | 3.53 Million USD | -107.559% |
| Optigenex Inc. | 1.28 Million USD | -470.168% |
| PharmChem, Inc. | 2.93 Million USD | -150.51% |
| Proteome Sciences plc | 3.26 Million USD | -124.694% |
| Response Genetics, Inc | 25.31 Million USD | 70.998% |
| Rennova Health, Inc. | 7.67 Million USD | 4.36% |
| RushNet, Inc. | 1.78 Million USD | -310.38% |
| ScreenPro Security Inc. | 3.23 Million USD | -126.712% |
| Stella Diagnostics Inc. | 11.42 Million USD | 35.739% |
| Todos Medical Ltd. | 14.05 Million USD | 47.766% |